Improved effect of an antiangiogenic tyrosine kinase inhibitor (SU5416) by combinations with fractionated radiotherapy or low molecular weight heparin.

@article{Lund2003ImprovedEO,
  title={Improved effect of an antiangiogenic tyrosine kinase inhibitor (SU5416) by combinations with fractionated radiotherapy or low molecular weight heparin.},
  author={Eva L\obner Lund and Minna W Br{\ae}ndholt Olsen and Kenneth E Lipson and Gerald McMahon and Anthony R. Howlett and Paul E. G. Kristjansen},
  journal={Neoplasia},
  year={2003},
  volume={5 2},
  pages={155-60}
}
The effect of combining SU5416 with fractionated radiotherapy or with low molecular weight (LMW) heparin (dalteparin) was studied in U87 human glioblastoma xenografts in nude mice. SU5416 is antiangiogenic by a specific inhibition of the vascular endothelial growth factor receptor 2 (VEGFR-2), and heparins are assumed to bind VEGF. Both SU5416 (100 mg/kg every second day in 5 days) and 3 Gyx5 produced moderate, yet significant, growth inhibition. Tumors treated with concomitant irradiation and… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

Dalteparin, a low-molecular-weight heparin, promotes angiogenesis mediated by heparin-binding VEGF-A in vivo

APMIS : acta pathologica, microbiologica, et immunologica Scandinavica • 2010
View 1 Excerpt

Low-molecular-weight heparins and angiogenesis.

APMIS : acta pathologica, microbiologica, et immunologica Scandinavica • 2006

References

Publications referenced by this paper.
Showing 1-10 of 25 references

Low-molecular-weight heparin and cancer.

Seminars in thrombosis and hemostasis • 2000
View 1 Excerpt

Similar Papers

Loading similar papers…